Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01352286 · OUTCOME

Adverse Events Related to Study Treatment

Redirected Auto T Cells for Advanced Myeloma · Source last updated 2019-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Day -40 to Year 1 post-treatment

What was measured

Number of Participants with Adverse Events related to study treatment

Analysis population: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT

Groups in this outcome

NYESO-1ᶜ²⁵⁹T Cells

Participants who received NYESO-1ᶜ²⁵⁹T following ASCT

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NYESO-1ᶜ²⁵⁹T Cells25

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells24Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        24
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Number of Participants with Adverse Events related to study treatment
groups
  1. description
    Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
    id
    OG000
    title
    NYESO-1ᶜ²⁵⁹T Cells
param Type
NUMBER
population Description
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
reporting Status
POSTED
time Frame
Day -40 to Year 1 post-treatment
title
Adverse Events Related to Study Treatment
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice